Elevance Health Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones09-19

DJ Elevance Health Inc. Stock Underperforms Wednesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Elevance Health Inc. (ELV) shed 0.75% to $539.46 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.29% to 5,618.26 and Dow Jones Industrial Average falling 0.25% to 41,503.10.

This was the stock's second consecutive day of losses.

Elevance Health Inc. closed $27.80 short of its 52-week high ($567.26), which the company achieved on September 3rd.

The stock underperformed when compared to some of its competitors Wednesday, as UnitedHealth Group Inc. $(UNH)$ rose 0.47% to $580.65, Cigna Group $(CI)$ fell 0.24% to $355.39, and Humana Inc. $(HUM)$ rose 1.12% to $315.29.

Trading volume (839,076) remained 138,200 below its 50-day average volume of 977,276.

Data source: Dow Jones Market Data, FactSet. Data compiled September 18, 2024.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

September 18, 2024 16:41 ET (20:41 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment